Privia Health Group saw its IBD SmartSelect Composite Rating jump to 96 Thursday, up from 94 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
Privia Health Group is not currently near a proper buy zone. Look for the stock to form and break out of a new chart pattern.
The stock sports a 98 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 98% of all stocks.
Its Accumulation/Distribution Rating of C shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
In Q1, the company reported 22% earnings growth. Revenue growth increased 16%, up from 5% in the prior report. That marks one quarter of accelerating revenue growth.
Privia Health Group earns the No. 4 rank among its peers in the Computer Software-Medical industry group. Veeva Systems Cl A is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
